Metvix (Methyl Aminolevulinate)

Methyl aminolevulinate penetrates skin cells and is converted intracellularly to protoporphyrin IX, a photosensitizer. When the area is illuminated with a specific wavelength of light, protoporphyrin IX generates reactive oxygen species that cause selective cytotoxicity of abnormal cells while sparing normal tissue.

The prescribed amount, frequency, and duration of Metvix application are determined by the treating physician based on lesion type, size, and treatment protocol. Dosing is individualized and should follow the prescriber's instructions.

The safety of Metvix in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the prescribing clinician.

Enquiries for Metvix can be submitted on the product page at gnhindia.com by specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metvix (methyl aminolevulinate) is a second‑generation photosensitizer that typically requires a shorter incubation time and lower light dose compared with first‑generation agents such as 5‑aminolevulinic acid. It offers comparable efficacy with potentially reduced treatment duration and improved patient convenience.

Metvix should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept away from direct light, moisture and extreme temperatures to maintain product stability.

Metvix is applied as a thin layer of cream to the target skin area by a qualified healthcare professional. After a prescribed incubation period, the treated area is illuminated with a specific light source to activate the photosensitizer. The procedure is performed under controlled clinical conditions.

Serious risks include severe photosensitivity reactions extending beyond the treated zone, allergic dermatitis, secondary infection of the lesion, and persistent ulceration or scarring. Patients should be monitored closely, and treatment should be stopped if any of these events occur.

Metvix is contraindicated in patients with known hypersensitivity to methyl aminolevulinate or any component of the formulation, in individuals with porphyria, and in those who cannot avoid light exposure after treatment. Caution is also advised for immunocompromised patients and those on systemic photosensitizing medications.